US 12,270,809 B2
Method for the site-specific covalent cross-linking of antibodies to surfaces
Andrew Tsourkas, Bryn Mawr, PA (US); and James Z Hui, Philadelphia, PA (US)
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Oct. 22, 2021, as Appl. No. 17/508,742.
Application 17/508,742 is a continuation of application No. 14/774,883, granted, now 11,156,608, previously published as PCT/US2014/030457, filed on Mar. 17, 2014.
Claims priority of provisional application 61/800,926, filed on Mar. 15, 2013.
Prior Publication US 2022/0214337 A1, Jul. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/543 (2006.01); A61K 47/62 (2017.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); A61K 49/18 (2006.01); C07K 14/31 (2006.01); C07K 17/00 (2006.01); C07K 17/06 (2006.01); G01N 33/58 (2006.01)
CPC G01N 33/54353 (2013.01) [A61K 47/62 (2017.08); A61K 47/65 (2017.08); A61K 47/6855 (2017.08); A61K 49/1875 (2013.01); C07K 14/31 (2013.01); C07K 17/00 (2013.01); C07K 17/06 (2013.01); G01N 33/582 (2013.01); C07K 2319/30 (2013.01)] 25 Claims
OG exemplary drawing
 
1. A conjugate composition comprising a variant of protein Z comprising a photoreactive crosslinker that permits specific binding to an immunoglobulin Fc region, wherein the variant of protein Z comprises an amino acid sequence about sixty-one amino acids in length and which has at least 80% identity to the sequence set forth in SEQ ID NO: 1 with the photoreactive crosslinker substituted for or introduced at F13, Q32, K35, N28, N23, or L17.